Neurocatalyst : Investment on clinical validation studies

Open / close summary

The Paris Institute of Translational Neuroscience (IHU-A-ICM) has funded since 2017, projects dedicated to clinical proofs-of-concept.

KEY ELEMENTS AND ELIGIBILITY CRITERIA

The Paris Institute of Translational Neuroscience (IHU-A-ICM) has funded since 2017, projects dedicated to clinical proofs-of-concept in:
– innovative medical technologies
– drugs / compounds repositioning

This call for proposals is open to everyone working in the IHU perimeter.
NEUROCATALYST will award up to 150 000 Euros per project (After a go/no go phase to validate feasibility) and provide a dedicated project manager to develop the study.

SELECTION CRITERIA

An evaluation committee composed of intern and extern medical experts and specialists of intellectual property will review the projects according to 3 criteria:

  1. Capacity to generate strong intellectual property and allowing to pursue with a complete development program, and/or capacity to demonstrate a medico economical utility;
  2. Scientific quality and capacity to address an unmet medical need;
  3. Technical, methodological and regulatory feasibility, power of efficacy markers and their capacity to have early read-outs.

APPLICATION FORM CONTENT, CALENDAR

Download the application form

It includes:

  • Study synopsis
  • Project leaders
  • Scientific and medical rationale, competitive approaches
  • Research and tech transfer (intellectual property or medico-economical utility)
  • Budget and milestones

The project may be submitted in French or in English.

Submission deadline : 21 January 2020

Results : 31 March 2020

Contact : neurocatalyst@icm-institute.org

You can download this page on a  pdf format